Clinical Trials Logo

Capillary Leak Syndrome clinical trials

View clinical trials related to Capillary Leak Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT03480529 Completed - Clinical trials for Rheumatoid Arthritis

Monitoring the IMmUological TOXicity of Drugs

MIMUTOX
Start date: March 1, 2018
Phase:
Study type: Observational [Patient Registry]

Several drugs and chemotherapies seem to have an impact on the immunological system. This study investigates reports of immunological toxicities, including the International classification of disease ICD-10 codes M05, M32, I78 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

NCT ID: NCT03410771 Completed - Pharmacokinetics Clinical Trials

Bioelectrical Impedance Analysis as a Bedside Tool to Estimate Volume of Distribution of Hydrophilic Antimicrobials in Critically Ill Patients

Start date: October 1, 2015
Phase: N/A
Study type: Observational

Bioelectrical impedance analysis is studied as a bedside tool to estimate capillary leak in order to guide dosing of hydrophilic antimicrobials.

NCT ID: NCT02853682 Active, not recruiting - Clinical trials for Capillary Leak Syndrome

Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery

GLYNO
Start date: January 20, 2016
Phase:
Study type: Observational

The glycocalyx is a layer of proteins and complex sugars covering the endothelium of vessels. Its role as capillary filtration control is important. In case of alteration of the glycocalyx, experimental models and some clinical studies show an increased capillary leak responsible for interstitial edema. The analysis of glycocalyx in routine care is important to guide volume expansion. Indeed, the literature provides evidence about the poor prognosis of excess water and its impact on organ. This analysis challenge is to justify filling solution of choice according to the characteristic of this capillary leakage.

NCT ID: NCT00936325 Completed - Clinical trials for Systemic Capillary Leak Syndrome

Studies in the Pathogenesis of Systemic Capillary Leak Syndrome

Start date: August 24, 2009
Phase:
Study type: Observational

Background: - Systemic Capillary Leak Syndrome (SCLS) is a disorder of unknown cause characterized by episodes of life-threatening drop in blood pressure and leakage of fluids into tissues. The outcome from an episode of SCLS may be mild and resolve on its own, or may be severe and result in death. Although SCLS likely involves abnormalities in the cells lining blood vessels, the specific cause(s) of this disorder are not known. - The treatment of choice for an acute SCLS episode is intravenous fluids and drugs such as norepinephrine (adrenaline), which are given to keep blood pressure at a level that will maintain vital organ function. This may be followed by a course of intravenous steroids and IVIG. Currently, there is no cure, but IVIG has been effective in diminishing the frequency and/or intensity of SCLS episodes when given regularly, as long-term effective preventive therapy for many patients who experience recurrent episodes of SCLS. - This protocol is focused on understanding what causes SCLS with the hope that research findings will lead to the design of safe and more effective treatments. Objectives: - To investigate mechanisms that may cause Systemic Capillary Leak Syndrome. Eligibility: - Patients between 16 and older who have been diagnosed with SCLS. Patients who have been diagnosed with SCLS and are between the ages of 7 and 16 may participate off-site, by sending specimens to the NIH. Patients 16 and older who have been diagnosed with SCLS and cannot travel to the NIH may also participate off-site. - Patients must have a documented history of at least one episode of SCLS with all three of the following documented on at least one occasion: low blood volume, low blood pressure without cause, and evidence of protein leakage during the episode. A letter of a referral from a treating physician is also required. Design: - Patients seen on site will be evaluated at the National Institutes of Health (NIH) for approximately 4 to 5 days on an inpatient basis, and will undergo the following procedures: - Medical history and physical examination. - Blood samples for evaluation and research purposes, as well as possible genetic testing. - Apheresis procedure, if needed, to obtain a larger volume of blood cells for research. - Bone marrow biopsy, if medically indicated. - Other medically indicated tests, such as skin tests to check for possible allergic reactions. - Patients who have a capillary leak episode while at NIH will be treated with the standard of care for treating SCLS. - Patients will be discharged from the protocol 1 year after the NIH visit. - Patients participating off-site will be asked to collect and send specimens (such as blood) to the NIH for research purposes and evaluation. - Unaffected Biological relatives of SCLS patients and Unrelated Normal Volunteers may also enroll on the study. Relatives and Normal Volunteers may be asked to provide research samples for the study, such as skin biopsy and research blood specimens.